# Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock

> **NCT00604214** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 1696 (actual)

## Conditions studied

- Sepsis

## Interventions

- **DRUG:** Drotrecogin alfa (activated)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00604214
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2011-09
- **Final completion:** 2012-02
- **Target enrollment:** 1696 (ACTUAL)
- **Last updated:** 2012-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00604214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00604214, "Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00604214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*